KMDANasdaq

KAMADA LTD

Healthcare·Healthcare·Phase 3·Rehovot, Israel

KAMADA LTD (KMDA): 1 pipeline candidate · 1 upcoming catalyst · 2 clinical trials. Updated within the last hour.

6.0/10

BioSniper Score

4-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth3.3

1 candidate

Catalyst Momentum2.0

1 upcoming, next in ~1809d

Insider SignalN/A

N/A

A transparent, data-derived signal for KAMADA LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$431.3M

Cash

Quarterly Burn

$8.5M

Runway

Revenue

$44.7M

Cash Runway vs Catalysts

Upcoming catalyst timeline.

Today~65 mo out
Catalyst within runway

Pipeline (1 candidate)

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

39

Total value held

$511.9M

HolderSharesValue
wells fargo & company/mn597,236$493.5M
renaissance technologies llc762,948$6.4M
ark investment management llc269,557$2.2M
two sigma investments, lp194,245$1.6M
envestnet asset management inc166,136$1.4M
marshall wace, llp149,993$1.3M
renaissance group llc125,901$1.1M
goldman sachs group inc72,955$608K
man group plc54,758$457K
millennium management llc46,934$391K

Showing top 10 of 39 institutional holders of KAMADA LTD. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

2 clinical trials·CEO: Mr. Amir London

Frequently asked questions

How many drug candidates are in KAMADA LTD's pipeline?

KAMADA LTD (KMDA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is KAMADA LTD's lead drug candidate?

KAMADA LTD's most advanced tracked candidate is alpha 1-antitrypsin (Phase 3) for Alpha 1-Antitrypsin Deficiency.

What is KAMADA LTD's next catalyst?

KAMADA LTD's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Prospective Phase 3 Multi-center 2-Year Placebo Controlled Double Blind Study to Evaluate the Effica" — expected June 1, 2031.

What is KAMADA LTD's market capitalization?

KAMADA LTD's market capitalization is approximately $431.3M.

Who is the CEO of KAMADA LTD?

Mr. Amir London is the chief executive officer of KAMADA LTD (KMDA).

Get the full picture on KAMADA LTD

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.